In a filing, Enliven Therapeutics Inc revealed its CHIEF FINANCIAL OFFICER Hohl Benjamin unloaded Company’s shares for reported $22655.0 on Jul 10 ’25. In the deal valued at $22.66 per share,1,000 shares were sold. As a result of this transaction, Hohl Benjamin now holds 23,000 shares worth roughly $0.5 million.
Then, Patel Anish sold 6,667 shares, generating $131,951 in total proceeds. Upon selling the shares at $19.79, the CHIEF OPERATING OFFICER now owns 296,642 shares.
Before that, Patel Anish bought 6,667 shares. Enliven Therapeutics Inc shares valued at $138,207 were divested by the Officer at a price of $20.73 per share.
Goldman initiated its Enliven Therapeutics Inc [ELVN] rating to a Buy in a research note published on June 16, 2025; the price target was $37. A number of analysts have revised their coverage, including BTIG Research’s analysts, who began to cover the stock in mid December with a ‘”a Buy”‘ rating. H.C. Wainwright began covering ELVN with “Buy” recommendation on September 09, 2024. Robert W. Baird started covering the stock on June 11, 2024. It rated ELVN as “an Outperform”.
Price Performance Review of ELVN
On Tuesday, Enliven Therapeutics Inc [NASDAQ:ELVN] saw its stock fall -5.87% to $21.65. Over the last five days, the stock has gained 8.63%. Enliven Therapeutics Inc shares have fallen nearly -10.02% since the year began. Nevertheless, the stocks have fallen -3.78% over the past one year. While a 52-week high of $30.03 was reached on 01/03/25, a 52-week low of $13.30 was recorded on 04/10/25.
Levels Of Support And Resistance For ELVN Stock
The 24-hour chart illustrates a support level at 20.85, which if violated will result in even more drops to 20.04. On the upside, there is a resistance level at 22.95. A further resistance level may holdings at 24.24.
How much short interest is there in Enliven Therapeutics Inc?
A steep rise in short interest was recorded in Enliven Therapeutics Inc stocks on 2025-06-13, growing by 83464.0 shares to a total of 6.62 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 6.54 million shares. There was a rise of 1.26%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on April 09, 2024 when Mizuho began covering the stock and recommended ‘”a Buy”‘ rating along with a $34 price target.
